Gothenburg University Vaccine Research Institute (GUVAX), Department of Microbiology and Immunology, University of Gothenburg, Box 435, 405 30, Gothenburg, Sweden.
Vaccine. 2012 Jun 6;30(26):3897-907. doi: 10.1016/j.vaccine.2012.03.082. Epub 2012 Apr 12.
Intranasal exposure to Streptococcus pneumoniae as well as mucosal or parenteral immunization with a recently developed killed pneumococcal whole cell vaccine, confer Th17-mediated protection against subsequent S. pneumoniae colonization in mice. Given our interest in the function of Th17 cells and the ongoing efforts to develop this vaccine for use in infants and children in developing countries, we analyzed Th17 responses to the whole cell antigen (WCA) and individual pneumococcal antigens in healthy individuals and patients with pneumococcal disease and compared responses in children and adults from Sweden and Bangladesh. Peripheral blood mononuclear cells (PBMCs) isolated from Swedish adults produced IL-17A after stimulation with WCA, with the pneumolysoid PdT and with the protein required for cell separation in group B streptococci (PcsB). IL-22 and IFN-γ responses were also detected, but these cytokines originated from separate CD4+ T cell subsets. PBMCs from Swedish children produced lower levels of IL-17A in response to WCA compared to adults, whereas no such difference was noted from the samples from Bangladesh, where responses by children and adults were both significantly higher than those in Sweden. High IL-17A responses to stimulation with WCA were also observed in children with proven or probable pneumococcal pneumonia. Our results thus demonstrate the presence of Th17-type T cells that are specific for pneumococcus in both children and adults. The different levels of Th17 responses to pneumococci in children and adults in developing and developed countries, which may at least partly be due to differences in exposure to pneumococci, are important factors to consider in the evaluation of candidate pneumococcal protein-based vaccines in human trials.
鼻腔内接触肺炎链球菌以及使用最近开发的经处理的肺炎链球菌全细胞疫苗进行黏膜或肠胃外免疫,可在小鼠中诱导 Th17 介导的针对随后的肺炎链球菌定植的保护作用。鉴于我们对 Th17 细胞功能的兴趣,以及为发展中国家的婴儿和儿童开发这种疫苗的持续努力,我们分析了健康个体和肺炎球菌病患者对全细胞抗原(WCA)和单个肺炎球菌抗原的 Th17 反应,并比较了来自瑞典和孟加拉国的儿童和成人的反应。从瑞典成年人中分离出的外周血单核细胞(PBMC)在用 WCA、肺炎球菌溶解素 PdT 和 B 群链球菌分离所需的蛋白(PcsB)刺激后产生了 IL-17A,同时也检测到了 IL-22 和 IFN-γ 的反应,但这些细胞因子来自于不同的 CD4+T 细胞亚群。与成年人相比,瑞典儿童对 WCA 的反应产生的 IL-17A 水平较低,而来自孟加拉国的样本则没有这种差异,来自儿童和成年人的反应都明显高于瑞典。在确诊或疑似肺炎球菌性肺炎的儿童中,用 WCA 刺激也观察到了高水平的 IL-17A 反应。因此,我们的研究结果表明,在儿童和成人中都存在针对肺炎链球菌的 Th17 型 T 细胞。在发展中国家和发达国家的儿童和成人中,针对肺炎球菌的 Th17 反应水平不同,这至少部分归因于对肺炎球菌的接触差异,这是在人类试验中评估候选肺炎球菌蛋白疫苗时需要考虑的重要因素。